ODI Pharma AB: Publication of year-end report
ODI Pharma AB (“ODI” or “the Company”) hereby publishes its year-end report for the period July 2019 – June 2020. The report is available...
top of page
News
We're thrilled to share the latest developments from our company.
Suche
ODI Pharma
28. Mai 20201 Min. Lesezeit
ODI Pharma AB: update – missing MAR label in quarterly report
ODI Pharma AB (“ODI” or “the Company”) gives an update regarding that a MAR label was missing in the quarterly report published 28th of...
0 Kommentare
ODI Pharma
28. Mai 20203 Min. Lesezeit
ODI Pharma AB: Publication of interim report for the first quarter 2020
ODI Pharma AB (“ODI” or “the Company”) hereby publishes its interim report for the period July 2019 – March 2020. The report is available...
0 Kommentare
ODI Pharma
7. Apr. 20202 Min. Lesezeit
ODI Pharma AB: Status update in connection to COVID-19
ODI Pharma AB (“ODI” or “the Company”) hereby announces that the Board of Directors does not see any impact on the Company’s mid- and...
0 Kommentare
ODI Pharma
27. Feb. 20203 Min. Lesezeit
ODI Pharma AB: Publication of half-yearly report 2019
ODI Pharma AB (“ODI” or “the Company”) hereby publishes its half-yearly report for the period October – December 2019. The report is...
0 Kommentare
ODI Pharma
23. Jan. 20201 Min. Lesezeit
Aphria Inc. received its EU-GMP certification
ODI Pharma AB (“ODI Pharma” or “the Company”) hereby announce that Aphria Inc. (“Aphria”), the Company’s supplier of medical cannabis,...
0 Kommentare
ODI Pharma
20. Jan. 20202 Min. Lesezeit
Final registration of ODI Pharma’s new share issue completed
Stockholm, 20.01.2020. As communicated earlier today, ODI Pharma AB's (“ODI Pharma” or “Company”) recently completed new share issue has...
0 Kommentare
ODI Pharma
20. Jan. 20202 Min. Lesezeit
First registration of ODI Pharma’s new share issue completed
Stockholm, 20.01.2020. ODI Pharma AB's ("ODI Pharma" or "Company") recently completed new share issue was significantly oversubscribed...
0 Kommentare
ODI Pharma
3. Jan. 20203 Min. Lesezeit
ODI Pharma’s new share issue prior to listing significantly oversubscribed
The subscription period in ODI Pharma AB's ("ODI Pharma" or "Company") new share issue prior to listing on Spotlight Stock Market was...
0 Kommentare
ODI Pharma
16. Dez. 20194 Min. Lesezeit
ODI Pharma has been approved for listing on Spotlight Stock Market, subscription period starts today
ODI Pharma AB (“ODI Pharma” or “the Company”), a medical cannabis finished product producer, today announces that the Company has been...
0 Kommentare
ODI Pharma
2. Aug. 20192 Min. Lesezeit
ODI Pharma Group announces consolidation under Swedish holding company, ODI Pharma AB
Zug/Switzerland, August 2nd, 2019 - The board of ODI Pharma Schweiz AG announces that its operations will be consolidated shortly under a...
0 Kommentare
bottom of page